Beaver County Employers Retirement Fund v. Avalanche Biotechnologies Inc.

     Shares are trading at 86 percent below what they went for in Avalanche’s $163 million second offering, building on a $102 million IPO the year before, because the macular-degeneration treatment it had hyped was a total bust, shareholders claim.

%d bloggers like this: